Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,290 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasms, Head and Neck Clear all
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

NCT01100619
View directory record Official record
Conditions
Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
Interventions
rosiglitazone, XL184
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Phase 1 Interventional

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
Interventions
Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
1,394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Completed No phase listed Observational

Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation

NCT01568723
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
response to therapy
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

NCT04504669
View directory record Official record
Conditions
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
Interventions
AZD8701, Durvalumab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 101 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Not applicable Interventional

Radiofrequency Ablation Study in LatinX Patients

NCT05903196
View directory record Official record
Conditions
Thyroid Nodule
Interventions
Mygen V-1000 RF system
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

NCT00524186
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
fluorouracil, irinotecan hydrochloride, leucovorin calcium, sunitinib malate, flow cytometry, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

NCT02262741
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
MEDI4736, tremelimumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
21
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Not listed Phase 2 Interventional

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

NCT05182866
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
ASP-1929 Photoimmunotherapy
Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

NCT04458259
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
PF-07265807, Sasanlimab, Axitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Cabozantinib, Placebo
Drug
Lead sponsor
Exelixis
Industry
Eligibility
16 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
31
States / cities
Newport Beach, California • Sacramento, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

NCT01194466
View directory record Official record
Conditions
Head Cancer, Neck Cancer, Pain
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Jennifer E. Lee
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 4, 2026, 1:24 PM EDT
Suspended Phase 2Phase 3 Interventional

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

NCT01810913
View directory record Official record
Conditions
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
Drug · Procedure · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
338
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional

The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors

NCT05798780
View directory record Official record
Conditions
Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
Interventions
ENHANCE Intervention - Exercise and Nutrition, ENHANCE Intervention - Nutrition Only
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Results available

Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer

NCT04477759
View directory record Official record
Conditions
Head and Neck Neoplasm
Interventions
50 Gy Radiation Therapy, 55 Gy Radiation Therapy, 60 Gy Radiation Therapy, Concurrent Atezolizumab, Adjuvant Atezolizumab
Radiation · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated No phase listed Observational

Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas

NCT00639405
View directory record Official record
Conditions
Parathyroid Neoplasm, Parathyroid Diseases
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 4, 2026, 1:24 PM EDT
Withdrawn No phase listed Observational

Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey

NCT02726282
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Withdrawn Phase 2 Interventional

Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer

NCT03234842
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Proton Beam Therapy, Photon Radiation Therapy, Chemotherapy
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

NCT01748942
View directory record Official record
Conditions
Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Interventions
Dexamethasone, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Transoral Robotic Surgery
Drug · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

NCT01520389
View directory record Official record
Conditions
Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer
Interventions
MM-151, MM-151 + irinotecan
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies

NCT02048917
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer
Interventions
High Intensity Counseling + Long Acting NRT + PRN NRT, High Intensity Counseling + bupropion + PRN NRT, High Intensity Counseling + varenicline + PRN NRT, High Intensity Counseling + Long Acting NRT, High Intensity Counseling + bupropion, High Intensity Counseling + varenicline, Low Intensity Counseling + Long Acting NRT + PRN NRT, Low Intensity Counseling + bupropion + PRN NRT, Low Intensity Counseling + varenicline + PRN NRT, Low Intensity Counseling + Long Acting NRT, Low Intensity Counseling + bupropion, Low Intensity Counseling + varenicline
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
10
States / cities
Ashland, Kentucky • Elizabethtown, Kentucky • Hazard, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

NCT00400374
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Not yet recruiting Not applicable Interventional

Resistance Training and Creatine Supplementation for Head and Neck Cancer

NCT07838090
View directory record Official record
Conditions
Head and Neck Cancer, Cancer Survivorship, Treatment-related Muscle Loss, Physical Function
Interventions
Creatine Supplementation, Resistance Training
Dietary Supplement · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer

NCT01693718
View directory record Official record
Conditions
Head and Neck
Interventions
Hydroxyurea, 5- Fluorouracil, Cisplatin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
59 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

NCT03349710
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Nivolumab, Cetuximab, Cisplatin, Radiotherapy
Biological · Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 4, 2026, 1:24 PM EDT